Artemisinins

"Artemisinins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A group of SESQUITERPENES and their analogs that contain a peroxide group (PEROXIDES) within an oxepin ring (OXEPINS).

Descriptor ID	D037621
MeSH Number(s)	D01.248.497.158.685.750.212 D01.339.431.374.212 D01.650.550.750.200 D02.389.338.055 D02.455.849.765.211
Concept/Terms	Artemisinins Artemisinins

Below are MeSH descriptors whose meaning is more general than "Artemisinins".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Electrolytes [D01.248]
Ions [D01.248.497]
Anions [D01.248.497.158]
Oxides [D01.248.497.158.685]
Peroxides [D01.248.497.158.685.750]
Artemisinins [D01.248.497.158.685.750.212]
Free Radicals [D01.339]
Reactive Oxygen Species [D01.339.431]
Peroxides [D01.339.431.374]
Artemisinins [D01.339.431.374.212]
Oxygen Compounds [D01.650]
Oxides [D01.650.550]
Peroxides [D01.650.550.750]
Artemisinins [D01.650.550.750.200]
Organic Chemicals [D02]
Free Radicals [D02.389]
Peroxides [D02.389.338]
Artemisinins [D02.389.338.055]
Hydrocarbons [D02.455]
Terpenes [D02.455.849]
Sesquiterpenes [D02.455.849.765]
Artemisinins [D02.455.849.765.211]

Below are MeSH descriptors whose meaning is related to "Artemisinins".

Below are MeSH descriptors whose meaning is more specific than "Artemisinins".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Artemisinins" by people in this website by year, and whether "Artemisinins" was a major or minor topic of these publications.

Bar chart showing 31 publications over 13 distinct years, with a maximum of 7 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2012	0	1	1
2014	2	0	2
2015	1	1	2
2016	3	1	4
2017	2	1	3
2018	1	1	2
2020	1	1	2
2021	1	0	1
2022	1	0	1
2023	2	0	2
2024	7	0	7
2025	2	1	3

Below are the most recent publications written about "Artemisinins" by people in Profiles.

Martin AC, Sadler JM, Simkin A, Musonda M, Katowa B, Matoba J, Schue J, Simulundu E, Bailey JA, Moss WJ, Juliano JJ, Fola AA. Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia. J Infect Dis. 2025 Oct 15; 232(4):918-922.

View in: PubMed
Meier-Scherling CPG, Watson OJ, Asua V, Ghinai I, Katairo T, Garg S, Conrad MD, Rosenthal PJ, Okell LC, Bailey JA. Selection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study. Lancet Microbe. 2025 May; 6(5):101027.

View in: PubMed
Wernsman Young N, Gashema P, Giesbrecht D, Munyaneza T, Maisha F, Mwebembezi F, Budodo R, Leonetti A, Crudale R, Iradukunda V, Jean Bosco N, Kirby RI, Boyce RM, Mandara CI, Kanyankole GK, Ntaro M, Okell LC, Watson OJ, Mulogo E, Ishengoma DS, Hangi S, Karema C, Mazarati JB, Juliano JJ, Bailey JA. High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing. J Infect Dis. 2025 Feb 04; 231(1):269-280.

View in: PubMed
Okitwi M, Shoue DA, Checkley LA, Orena S, Ceja FG, Taremwa Y, Tumwebaze PK, Katairo T, Byaruhanga O, Sievert MA, Garg S, Kreutzfeld OK, Legac J, Bailey JA, Nsobya SL, Conrad MD, Rosenthal PJ, Ferdig MT, Cooper RA. The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2024 12 05; 68(12):e0118324.

View in: PubMed
Fola AA, Kobayashi T, Hamapumbu H, Musonda M, Katowa B, Matoba J, Stevenson JC, Norris DE, Thuma PE, Wesolowski A, Moss WJ, Juliano JJ, Bailey JA. Temporal genomics in Southern Zambia shows rising prevalence of Plasmodium falciparum mutations linked to delayed clearance after artemisinin-lumefantrine treatment. Sci Rep. 2024 11 05; 14(1):26789.

View in: PubMed
Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, Francis F, Buguzi CC, Moshi R, Garimo I, Lazaro S, Lusasi A, Aaron S, Chacky F, Mohamed A, Njau RJA, Kitau J, Rasmussen C, Bailey JA, Juliano JJ, Warsame M. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024 Nov; 24(11):1225-1233.

View in: PubMed
Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, Bakari C, Madebe RA, Seth MD, Mandara CI, Popkin-Hall ZR, Moshi R, Mbwambo RB, Niar? K, MacInnis B, Francis F, Mbwambo D, Garimo I, Chacky F, Aaron S, Lusasi A, Molteni F, Njau RJA, Nhiga SL, Mohamed A, Bailey JA, Ishengoma DS. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13?regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. 2024 Oct; 5(10):100920.

View in: PubMed
Ishengoma DS, Gosling R, Martinez-Vega R, Beshir KB, Bailey JA, Chimumbwa J, Sutherland C, Conrad MD, Tadesse FG, Juliano JJ, Kamya MR, Mbacham WF, M?nard D, Rosenthal PJ, Raman J, Tatarsky A, Tessema SK, Fidock DA, Djimde AA. Urgent action is needed to confront artemisinin partial resistance in African malaria parasites. Nat Med. 2024 Jul; 30(7):1807-1808.

View in: PubMed
Schreidah C, Giesbrecht D, Gashema P, Young NW, Munyaneza T, Muvunyi CM, Thwai K, Mazarati JB, Bailey JA, Juliano JJ, Karema C. Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda. Malar J. 2024 May 16; 23(1):150.

View in: PubMed
Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, Rasmussen C, Tadesse FG, Uwimana A, Fidock DA. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024 Sep; 24(9):e591-e600.

View in: PubMed

People

Explore

Similar Concepts

Top Journals